Effectiveness of PPI treatment and guideline adherence in 236 patients with eosinophilic oesophagitis-Results from the population-based DanEoE cohort shows a low complication rate.
Adult
Denmark
/ epidemiology
Dose-Response Relationship, Drug
Eosinophilic Esophagitis
/ drug therapy
Eosinophils
/ drug effects
Guideline Adherence
/ statistics & numerical data
Humans
Leukocyte Count
Practice Guidelines as Topic
Proton Pump Inhibitors
/ administration & dosage
Registries
Remission Induction
Retrospective Studies
Treatment Outcome
complications
eosinophilic oesophagitis
oesophagus
proton pump inhibitors
treatment
Journal
United European gastroenterology journal
ISSN: 2050-6414
Titre abrégé: United European Gastroenterol J
Pays: England
ID NLM: 101606807
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
12
05
2021
accepted:
14
07
2021
pubmed:
4
9
2021
medline:
28
1
2022
entrez:
3
9
2021
Statut:
ppublish
Résumé
Proton pump inhibitors (PPIs) are often the first drug of choice in the treatment of eosinophilic oesophagitis (EoE), and in Denmark 8 weeks of high-dose PPI therapy is recommended as first-line treatment followed by rebiopsying, reflecting international recommendations. To assess the population-based effectiveness of PPIs in the treatment of EoE and evaluate whether patients were treated and followed according to the regional guideline. This is a retrospective, registry-based, DanEoE cohort study of 236 adult EoE patients diagnosed between 2007 and 2017 in the North Denmark Region. After patient file revision, the EoE diagnosis was defined according to the AGREE 2 consensus. Symptomatic PPI response was defined as complete symptom resolution and histological remission (<15 eosinophils per high-power field). PPI treatment was initiated in 92% of the EoE patients. High- and low-dose PPIs were prescribed in 55% and 45% of the cases, respectively. When treated with high-dose PPIs, 68% of the patients were completely symptom-free, and 49% were in histological remission. In 39% of high-dose PPI-treated patients, the symptomatic and histological responses were conflicting. While treated with PPIs, complications were rare, with <5% strictures in responders and <10% in non-responders. Rebiopsying was done in 67% of the EoE patients started on PPIs. High-dose PPI treatment was effective in half of the EoE patients started on PPIs, but conflicting symptomatic and histological PPI responses were common. Complications were rare when PPIs were started. One-third of the patients were not rebiopsied as recommended.
Sections du résumé
BACKGROUND
Proton pump inhibitors (PPIs) are often the first drug of choice in the treatment of eosinophilic oesophagitis (EoE), and in Denmark 8 weeks of high-dose PPI therapy is recommended as first-line treatment followed by rebiopsying, reflecting international recommendations.
AIMS
To assess the population-based effectiveness of PPIs in the treatment of EoE and evaluate whether patients were treated and followed according to the regional guideline.
METHODS
This is a retrospective, registry-based, DanEoE cohort study of 236 adult EoE patients diagnosed between 2007 and 2017 in the North Denmark Region. After patient file revision, the EoE diagnosis was defined according to the AGREE 2 consensus. Symptomatic PPI response was defined as complete symptom resolution and histological remission (<15 eosinophils per high-power field).
RESULTS
PPI treatment was initiated in 92% of the EoE patients. High- and low-dose PPIs were prescribed in 55% and 45% of the cases, respectively. When treated with high-dose PPIs, 68% of the patients were completely symptom-free, and 49% were in histological remission. In 39% of high-dose PPI-treated patients, the symptomatic and histological responses were conflicting. While treated with PPIs, complications were rare, with <5% strictures in responders and <10% in non-responders. Rebiopsying was done in 67% of the EoE patients started on PPIs.
CONCLUSIONS
High-dose PPI treatment was effective in half of the EoE patients started on PPIs, but conflicting symptomatic and histological PPI responses were common. Complications were rare when PPIs were started. One-third of the patients were not rebiopsied as recommended.
Identifiants
pubmed: 34477326
doi: 10.1002/ueg2.12146
pmc: PMC8498393
doi:
Substances chimiques
Proton Pump Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
910-918Informations de copyright
© 2021 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology.
Références
J Allergy Clin Immunol. 2020 Jan;145(1):1-7
pubmed: 31910983
Science. 2003 Jul 11;301(5630):163
pubmed: 12855788
Clin Epidemiol. 2010 Aug 09;2:51-6
pubmed: 20865103
Aliment Pharmacol Ther. 2019 May;49(9):1116-1125
pubmed: 30887555
Clin Gastroenterol Hepatol. 2016 Jan;14(1):13-22.e1
pubmed: 26247167
Dis Esophagus. 2010 Jul;23(5):377-85
pubmed: 20353444
Clin Gastroenterol Hepatol. 2009 Dec;7(12):1305-13; quiz 1261
pubmed: 19733260
Science. 2000 Mar 31;287(5462):2398-9
pubmed: 10766613
Thorac Surg Clin. 2011 Nov;21(4):575-87
pubmed: 22040638
Gastroenterology. 1996 Jul;111(1):85-92
pubmed: 8698230
Am J Gastroenterol. 2006 Aug;101(8):1900-20; quiz 1943
pubmed: 16928254
United European Gastroenterol J. 2017 Apr;5(3):335-358
pubmed: 28507746
Gastrointest Endosc. 2003 Oct;58(4):516-22
pubmed: 14520283
United European Gastroenterol J. 2018 Feb;6(1):29-37
pubmed: 29435311
Aliment Pharmacol Ther. 2014 Oct;40(8):955-65
pubmed: 25112708
J Pediatr Gastroenterol Nutr. 2020 Oct;71(4):524-529
pubmed: 32541201
Gastroenterology. 2007 Oct;133(4):1342-63
pubmed: 17919504
Clin Gastroenterol Hepatol. 2020 Dec;18(13):2903-2911.e4
pubmed: 31988045
Aliment Pharmacol Ther. 2020 Sep;52(5):798-807
pubmed: 32677040
J Allergy Clin Immunol. 2011 Jul;128(1):3-20.e6; quiz 21-2
pubmed: 21477849
United European Gastroenterol J. 2021 Jul;9(6):688-698
pubmed: 34117730
Am J Gastroenterol. 2018 Jun;113(6):836-844
pubmed: 29700481
Gastrointest Endosc. 2014 Apr;79(4):577-85.e4
pubmed: 24275329
Gastroenterology. 2018 Oct;155(4):1022-1033.e10
pubmed: 30009819
Dis Esophagus. 2018 Aug 1;31(8):
pubmed: 29617744
Clin Gastroenterol Hepatol. 2009 Oct;7(10):1055-61
pubmed: 19577011
Lancet. 2009 Mar 7;373(9666):850-61
pubmed: 19269522
United European Gastroenterol J. 2021 Oct;9(8):910-918
pubmed: 34477326
Lancet. 2018 Dec 23;390(10114):2769-2778
pubmed: 29050646
Endoscopy. 2021 Jan;53(1):15-24
pubmed: 32757199